Regulus Therapeutics Inc (NASDAQ:RGLS) shares saw unusually-high trading volume on Friday following insider buying activity. Approximately 4,278,434 shares were traded during mid-day trading, an increase of 364% from the previous session’s volume of 921,250 shares.The stock last traded at $1.40 and had previously closed at $1.25.
Specifically, Director Stelios Papadopoulos bought 500,000 shares of the stock in a transaction dated Wednesday, March 22nd. The stock was bought at an average cost of $1.22 per share, for a total transaction of $610,000.00. Following the completion of the purchase, the director now owns 400,677 shares in the company, valued at approximately $488,825.94. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William H. Rastetter bought 250,000 shares of the stock in a transaction dated Tuesday, March 7th. The stock was acquired at an average price of $1.15 per share, with a total value of $287,500.00. The disclosure for this purchase can be found here. Corporate insiders own 2.30% of the company’s stock.
A number of analysts have recently weighed in on RGLS shares. Needham & Company LLC lowered Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 30th. Chardan Capital lowered their target price on Regulus Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, December 7th. Cantor Fitzgerald started coverage on Regulus Therapeutics in a research note on Friday, December 16th. They issued an “overweight” rating and a $11.00 target price for the company. Zacks Investment Research upgraded Regulus Therapeutics from a “sell” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Wednesday, January 18th. Finally, Wedbush restated an “outperform” rating and issued a $13.00 target price (up from $8.00) on shares of Regulus Therapeutics in a research note on Monday, January 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $5.68.
The firm’s market capitalization is $74.10 million. The firm’s 50 day moving average price is $1.21 and its 200 day moving average price is $2.34.
Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, March 2nd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.01. Regulus Therapeutics had a negative net margin of 573.63% and a negative return on equity of 70.38%. Equities research analysts predict that Regulus Therapeutics Inc will post ($1.34) EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in RGLS. Piermont Capital Management Inc. increased its stake in Regulus Therapeutics by 9.3% in the third quarter. Piermont Capital Management Inc. now owns 166,104 shares of the biopharmaceutical company’s stock valued at $548,000 after buying an additional 14,180 shares during the period. Tudor Investment Corp Et Al purchased a new stake in Regulus Therapeutics during the fourth quarter valued at about $105,000. A.R.T. Advisors LLC increased its stake in Regulus Therapeutics by 405.0% in the fourth quarter. A.R.T. Advisors LLC now owns 90,400 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 72,500 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Regulus Therapeutics by 23.4% in the third quarter. Wells Fargo & Company MN now owns 630,332 shares of the biopharmaceutical company’s stock valued at $2,081,000 after buying an additional 119,668 shares during the period. Institutional investors and hedge funds own 50.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Regulus Therapeutics Inc (RGLS) Sees Unusually-High Trading Volume on Insider Buying Activity” was first posted by Web Breaking News and is owned by of Web Breaking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at http://www.webbreakingnews.com/2017/03/26/regulus-therapeutics-inc-rgls-sees-unusually-high-trading-volume-on-insider-buying-activity.html.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.